Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.
Clin Cancer Res. 2024 Sep 3;30(17):3715-3725. doi: 10.1158/1078-0432.CCR-23-3874.
Clin Cancer Res. 2024.
PMID: 38546220
Free PMC article.
Clinical Trial.
Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma.
Karhapää H, Mäkelä S, Laurén H, Jaakkola M, Schalin-Jäntti C, Hernberg M.
Karhapää H, et al. Among authors: jaakkola m.
Endocr Connect. 2022 Feb 4;11(2):e210562. doi: 10.1530/EC-21-0562.
Endocr Connect. 2022.
PMID: 35015699
Free PMC article.
Item in Clipboard
BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients.
Kohtamäki LM, Hernberg M, Jaakkola M, Mäkelä S.
Kohtamäki LM, et al. Among authors: jaakkola m.
Melanoma Res. 2021 Jun 1;31(3):218-223. doi: 10.1097/CMR.0000000000000727.
Melanoma Res. 2021.
PMID: 33675299
Item in Clipboard
Cite
Cite